4.3 Article

Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants

期刊

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0000000000000222

关键词

antiretroviral therapy; raltegravir; cerebrospinal fluid concentrations; blood-cerebrospinal fluid barrier; adenosine triphosphate-binding cassette transporter G2

资金

  1. Grant for National Center for Global Health and Medicine [H22-110]
  2. Japanese Ministry of Health, Labour and Welfare [H23-AIDS-001]
  3. MSD
  4. Janssen Pharmaceutical
  5. Abbott
  6. Roche Diagnostics
  7. Pfizer

向作者/读者索取更多资源

Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据